Bimekizumab was noninferior and superior to adalimumab with respect to PASI 90 response and IGA score at Week 16. Bimekizumab is a promising IL-17A/F inhibitor that has shown clinical improvement in PsO patients compared to placebo and other IL inhibitors. Warren et al. compared the safety and efficacy of bimekizumab with adalimumab in a 56-week double-blind trial.

Participants were split into three randomised groups of bimekizumab or adalimumab treatment. Bimekizumab therapy showed an improved clinical response over adalimumab in all primary and secondary endpoints, both in patients who switched from adalimumab and those who received bimekizumab at baseline.

Keywords:


Publication thumbnail: Bimekizumab versus adalimumab in plaque psoriasis
LinkedIn